Z52 -L16 is Drug-Linker Conjugates for ADC, which is composed of a linker and a Ras inhibitor Z52. Z52 -L16 can be used for the research of cancer, such as pancreatic cancer [1].
In Vitro, ADCs (Antibody-Drug Conjugates) consist of antibodies that specifically target antigens, cleavable linkers, and highly active cytotoxic drugs. They enter target cells through antibody-mediated endocytosis and release the drug, thereby achieving the function of precisely killing target cells[1].
References:
[1]. Zhao Jichen, et al. Macrocyclic compound and antibody-drug conjugate thereof. WO2025051241A1. 2020-03-13
In Vitro, ADCs (Antibody-Drug Conjugates) consist of antibodies that specifically target antigens, cleavable linkers, and highly active cytotoxic drugs. They enter target cells through antibody-mediated endocytosis and release the drug, thereby achieving the function of precisely killing target cells[1].
References:
[1]. Zhao Jichen, et al. Macrocyclic compound and antibody-drug conjugate thereof. WO2025051241A1. 2020-03-13